News

Bionxt Solutions has launched the final animal study needed to prepare for human testing of BNT23001, its sublingual version of cladribine, in people with multiple sclerosis (MS). The 15-day dosing optimization study will compare Bionxt’s thin-film formulation with the approved tablet version of cladribine, sold as Mavenclad, in…

People with multiple sclerosis (MS) have altered levels of bacteria in their mouths, with reduced levels of normal healthy bacteria and higher levels of bacteria that can cause disease, a new study reports. “Your mouth may reveal more about your overall health than you think,” Ashutosh Mangalam, PhD, senior…

The first patient has been dosed in a Phase 1 clinical trial of Autolus Therapeutics‘ experimental CAR T-cell therapy, obecabtagene autoleucel (obe-cel), in people with progressive forms of multiple sclerosis (MS) who have failed to respond to existing treatments. Dosing took place at University College London Hospitals NHS…

Researchers have identified a protein that naturally slows myelin production — a finding that could lead to ways to repair myelin damage in multiple sclerosis (MS) and other neurological disorders. In mice, the protein (called Tfii-i) was found to limit the activity of genes that drive myelin formation. When…

Having a higher body mass index (BMI), a measure of body fat based on a person’s height and weight, at diagnosis is tied to faster disability progression in people with multiple sclerosis (MS), according to a recent study in Sweden. This effect was particularly pronounced when excess weight…

Signs of myelin damage are detectable about one year before damage to nerve fibers is apparent and about seven years before the onset of multiple sclerosis (MS) symptoms, a new study reveals. These findings shed new light on the timing of MS onset, and could open new avenues to…

A gene on the X chromosome that is more active in women than men appears to drive inflammation in the brain, helping to explain why women are more likely to develop neurological diseases such as multiple sclerosis (MS) and Alzheimer’s disease, according to a study out of the…

Liberate Bio’s CAR-M cell therapy almost completely depleted B-cells in nonhuman primates, suggesting the approach may be used to treat B-cell diseases such as multiple sclerosis (MS) and some cancers. The therapy is designed to genetically engineer monocytes and macrophages, two types of immune cells, to target and…

As a law student in the Czech Republic, Jana Hlavacova specialized in international law and international relations, but a multiple sclerosis (MS) diagnosis led her to shift her professional focus. Applying her legal expertise to her work at the Czechia Ministry of Health, she now helps shape healthcare policy…

Abnormal brain cells, known as disease-associated radial glia or DARGs, may play a key role in driving chronic inflammation in people with progressive forms of multiple sclerosis (MS), a new study shows. Based on the finding, researchers are now working to better understand the biology of DARGs, with an…

When Jill Blackburn’s daughter, Sierra, was diagnosed with pediatric multiple sclerosis (MS) at the age of 15, Blackburn had trouble finding sufficient support and resources. She eventually joined a relevant Facebook group, which she evolved into a nonprofit organization, the Pediatric Multiple Sclerosis Alliance. She now serves as…

People with multiple sclerosis (MS) are more than twice as likely to experience headaches, including migraines, than their healthy counterparts, a study from Greece found. Headaches were also longer and more intense for MS patients, and more likely to lead to the use of acute medication. “These findings suggest that headaches…

The U.S. Food and Drug Administration (FDA) has given Tr1x the green light to launch a first-in-human clinical trial of TRX319, a cell therapy candidate designed to restore immune balance in people with progressive forms of multiple sclerosis (MS). With FDA clearance now granted for its investigational new…

The U.S. Food and Drug Administration (FDA) granted fast track designation to EG110A, EG 427‘s DNA-based therapy to treat neurogenic detrusor overactivity (NDO) — a bladder disorder that can arise from spinal cord injury or neurodegenerative conditions such as multiple sclerosis (MS). The FDA gives fast track status to experimental…

Going through menopause with multiple sclerosis (MS) can be challenging, as the changes that come with this stage of life may interact or occur in tandem with existing MS symptoms. A team of researchers recently studied how menopause affects women living with MS, with their findings presented…

Seizures in people with multiple sclerosis (MS) may be driven by changes in levels of certain brain signaling molecules, implying that targeting these molecules may be a viable strategy to treat MS-related seizures, according to new research done in a mouse model. “If the same transporters and receptors are…

Kernal Biologics has been awarded up to $48 million in funding to accelerate the development of KR-402, a next-generation CAR T-cell therapy for multiple sclerosis (MS) and certain blood cancers. The funds come from the Advanced Research Projects Agency for Health’s (ARPA-H) EMBODY program, which aims to support the…

Researchers have identified two experimental medications that may promote myelin repair in people with multiple sclerosis (MS). The two compounds have shown promise in cell and animal models, and preclinical work is ongoing to bring them into clinical testing. The compounds were identified by academic researchers, but the program…

A new grant from the Valhalla Foundation will help Octave Bioscience advance the development of a biomarker blood test for detecting disease progression in people with multiple sclerosis (MS). The company is developing its MS Disease Progression test, or MSDP, to objectively measure MS progression based on…

Quantum Biopharma says it is closer to initiating a Phase 2 clinical trial — one involving people living with multiple sclerosis (MS) — to test its experimental therapy Lucid-MS after receiving the final reports from two toxicology studies requested by the U.S Food and Drug Administration (FDA). The…

Zenas Biopharma has acquired global rights to develop the BTK inhibitor orelabrutinib to treat multiple sclerosis (MS) and other diseases. The deal with orelabrutinib’s developer, Innocare Pharma, includes rights to two other investigational therapies. Zenas will pay Innocare up to $100 million in cash and up to…

Roxy Murray was living up to being known as “The Multiple Sclerosis Fashionista” when she attended the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Barcelona, Spain, on a warm September afternoon. Murray, who has multiple sclerosis (MS) and lives in London, applies her…

Disability progression does not seem to worsen in women with multiple sclerosis (MS) after they undergo menopause, according to the largest study of its kind. Instead, other factors such as older age at MS onset, longer disease duration, and worse initial disability scores were associated with an increased risk…

The world’s largest meeting on multiple sclerosis (MS) has wrapped up for the year, and the National Multiple Sclerosis Society (NMSS) played a central role in many of the advances highlighted there. Nearly 10,000 people attended the 41st Congress of the European Committee for Treatment and Research in Multiple…

Up to six years of continuous treatment with Briumvi (ublituximab) led to sustained reductions in relapse rates and a low rate of disability progression in people with relapsing forms of multiple sclerosis (MS), with no new safety concerns reported. That’s according to new long-term data from the…

Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium continues to show a significant effect on disability worsening in people with progressive forms of multiple sclerosis (MS), even in those without signs of active inflammation in the brain, a group with limited treatment options. That’s according to new data…

Increasing the dose of Ocrevus (ocrelizumab) by two- or threefold, depending on a person’s weight, did not provide additional benefit in slowing disability progression compared with the standard regimen in people with primary progressive multiple sclerosis (PPMS). That’s according to top-line data from the Phase 3b GAVOTTE…

Most people with relapsing forms of multiple sclerosis (MS) given Mavenclad (cladribine) did not experience confirmed disability progression for at least four years after starting on the approved therapy, according to new Phase 4 trial data. The results come from the CLARIFY-MS (NCT03369665) and MAGNIFY-MS (NCT03364036)…

Children and adolescents living with multiple sclerosis (MS) seem to benefit at least as much — and for some outcomes, significantly more — from Ocrevus (ocrelizumab) as from treatment with Gilenya (fingolimod), now the only MS therapy approved for pediatric patients in the U.S. That’s according to…

Frexalimab, a therapy Sanofi is developing for multiple sclerosis (MS) patients, led to sustained reductions in disease activity in people with relapsing forms of MS over more than two years of treatment, while continuing to show a favorable safety profile. That’s according to new data from an…